Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

ABSTRACT: A pan-cancer cohort of 1031 patients resistant to systemic therapies or with no approved therapeutic options. It includes whole-exome sequencing of 569 tumor and matched-normal samples, and transcriptome sequencing of 947 tumor samples. Biopsies were taken at entry into precision medicine trials, often after diagnosed resistance. Comprehensive clinical information is available for all patients and include patient age at biospy, tumor primary site and histological subtype, biopsy site, treatments received prior to biopsy, blood assessment results at biopsy, metastatic site at biopsy, and survival time from the biopsy date.

PROVIDER: EGAS00001006648 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

42b6c35b-7688-47f2-891f-c782bf7a8be6 - samples

Project description:A pan-cancer cohort of 1031 patients resistant to systemic therapies or with no approved therapeutic options. It includes whole-exome sequencing of 571 tumor and matched-normal samples, and transcriptome sequencing of 947 tumor samples. Biopsies were taken at entry into precision medicine trials, often after diagnosed resistance. Comprehensive clinical information is available for all patients and include patient age at biospy, tumor primary site and histological subtype, biopsy site, treatments received prior to biopsy, blood assessment results at biopsy, metastatic sites at biopsy, and survival time from the biopsy date.

| EGAD00001009684 | EGA

Pan-cancer ctDNA analysis

Project description:Pan-cancer circulating tumor DNA detection in over 10,000 real-world Chinese patients

| PRJEB36993 | ENA

A pan-cancer single-cell landscape of tumor-infiltrating myeloid cells

Project description:Tumor-infiltrating myeloid cells (TIMs) have emerged as key regulators in tumor progression, however, the similarity and discrepancy of the fundamental properties of these cells across different cancer types remain elusive. Here, we performed a pan-cancer analysis of TIM sub-populations in multiple human cancer types. Our comprehensive analyses provide valuable insights for understanding the TIM properties across multiple tumors.

2021-02-04 | GSE154763 | GEO

Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

Project description:T cells present diverse states in the tumor, playing a central role in cancer immunity and immunotherapies. However, their heterogeneity, dynamics and composition within tumors of various cancer types are not fully characterized. Integrating a pan-cancer single-cell RNA sequencing atlas of T cells cross multiple cancer types, we systematically characterized their diversity, identified the potentially tumor-reactive T cells, and revealed new cell types. Our findings provide new insights into T cell immunity and will facilitate immunotherapy development targeting T cells in human cancer.

2021-12-16 | GSE156728 | GEO

Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

Project description:Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

| PRJNA658913 | ENA

Pan troglodytes

Project description:Pan troglodytes Epigenomics

| PRJNA196647 | ENA

Pan-cancer tumor-specific antigens and membrane targets from transposable elements

Project description:Cryptic promoters within transposable elements (TEs) are transcriptionally reactivated in tumors to create novel TE-gene chimeric transcripts, which can produce immunogenic antigens. We performed the most comprehensive screen to date for these TE exaptation events in 33 TCGA tumor types, 675 cancer cell lines, and 11,686 GTEx adult tissue transcriptomes and identified 1,068 TE-exapted candidates with the potential to generate shared tumor-specific TE-chimeric antigens (TS-TEAs). Resultant whole lysate and HLA-pulldown mass spectrometry data confirmed that TS-TEAs are presented on cancer cell surfaces. In addition, we highlight the tumor-specific membrane proteins transcribed from TE promoters that can expose novel epitopes on the extracellular surface of cancer cells. Here, we showcase the high pan-cancer prevalence of TS-TEAs and atypical membrane proteins that can be therapeutically exploited through immunotherapy approaches.

2023-01-21 | PXD033351 | Pride

Pan troglodytes

Project description:Pan troglodytes Genome sequencing

| PRJNA214897 | ENA

Pan troglodytes

Project description:Pan troglodytes Genome sequencing

| PRJNA415617 | ENA

Pan-cancer molecular analysis of the RB-pathway

Project description:The retinoblastoma tumor suppressor (RB1) plays a critical role in coordinating multiple pathways that impact on tumor initiation, disease progression, and therapeutic responses. Here we interrogated the TCGA pan-cancer data collection to probe fundamental molecular features associated with the RB-pathway across 31 tumor-types. While the RB-pathway has been purported to exhibit multiple mutually exclusive events, only RB1 is mutually exclusive with multiple genetic events that deregulate CDK4/6 activity. Using an isogenic ER+ breast cancer model with targeted RB1 deletion, we identified gene expression features that link CDK4/6 activity and RB-dependency (CDK4/6-RB integrated signature). This gene expression signature is associated with prognosis across a spectrum of tumors that exhibit average lower signature value indicative of more indolent diseases. Single copy loss on chromosome 13q encompassing the RB1 locus is prevalent in many cancers, and is associated with reduced expression of multiple genes on 13q including RB1, and inversely related to the CDK4/6-RB integrated signature supporting a genetic cause/effect relationship. To probe the broader implications on tumor biology, we investigated genes that are positively and inversely correlated with the CDK4/6-RB integrated signature. This approach defined tumor-specific pathways that could represent new therapeutic vulnerabilities associated with RB-pathway activity.

2020-03-02 | GSE145316 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data